UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/532,563	12/05/2005	Jan-Henrik Ardenkjaer-Larsen	PN0283	6722
36335 7590 05/07/2010 GE HEALTHCARE, INC. IP DEPARTMENT 101 CARNEGIE CENTER			EXAMINER	
			SCHLIENTZ, LEAH H	
PRINCETON, NJ 08540-6231		ART UNIT	PAPER NUMBER	
			1618	
			MAIL DATE	DELIVERY MODE
			05/07/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Comments	10/532,563	ARDENKJAER-LARSEN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Leah Schlientz	1618				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	Lely filed the mailing date of this communication. (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>01 F</u>	ehruary 2010					
<i>'</i>	/ <del></del>					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
<ul> <li>4)  Claim(s) 1-9 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdra</li> <li>5)  Claim(s) is/are allowed.</li> <li>6)  Claim(s) 1-9 is/are rejected.</li> <li>7)  Claim(s) is/are objected to.</li> <li>8)  Claim(s) are subject to restriction and/or</li> </ul>						
Application Papers						
9)☐ The specification is objected to by the Examine	er.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
Attachment(s) 1) ☑ Notice of References Cited (PTO-892)	4) ☐ Interview Summary	(PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite				

Application/Control Number: 10/532,563 Page 2

Art Unit: 1618

#### **DETAILED ACTION**

## Acknowledgement of Receipt

Applicant's Response, filed 2/1/2010, in reply to the Office Action mailed 9/30/2009, is acknowledged and has been entered. Claim 10 has been cancelled. Claims 1-9 are pending and are examined herein on the merits for patentability.

## Response to Arguments

Applicant's arguments have been considered but are moot in view of new ground(s) of rejection.

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ardenkjaer-Larsen *et al.* (US 6,466,814) in view of Pines (US 6,426,058).

Ardenkjaer-Larsen teaches hyperpolarization of a nuclei effected by a hyperpolarizable gas, such as by (a) hyperpolarizing a hyperpolarizable gas before, during or after introducing a high T<sub>1</sub> agent thereto whereby to cause nuclear polarization of said high T1 agent; and b) dissolving in a physiologically tolerable solvent said high T<sub>1</sub> agent (column 19, lines 1-12). Physiologically tolerable solvent includes perfluorocarbon (column 3, line 8). Hyperpolarizable gas is preferably <sup>129</sup>Xe (column 19, line 28). It can be produced by irradiating agent e.g. with an electron spin resonance transition stimulating radiation (e.g. microwave radiation). For example, hyperpolarization of xenon can be accomplished by irradiating a polarizing agent whereby to cause dynamic nuclear polarization; polarizing agents include nitroxide, trityl, etcl (radicals) (column 19, lines 63 - column 20, line 9). Hyperpolarization could be done in either liquid or solid form, the radical could be added in pure form or bound to a matrix. After irradiation, heating of the sample could release hyperpolarized gas and a new batch of xenon could be condensed and irradiated (column 20, lines 10-30).

While Ardenkjaer-Larsen discloses a) hyperpolarising a hyperpolarisable gas before, during or after introducing a high  $T_1$  agent thereto and b) dissolving in a physiologically tolerable solvent (e.g. perfluorocarbon) said high  $T_1$  agent, rather than introduction of solvent prior to hyperpolarization of the hyperpolarisable gas, it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the order of addition of solvent in the process of Ardenkjaer-Larsen.

Page 4

Pines teaches that it can be advantageous to dissolve a noble gas in a liquid prior to hyperpolarizing the noble gas (column 9, lines 25-30). Prefered noble gases include xenon, helium, etc. (column 9, lines 5-10). Suitable liquids/fluids include fluorocarbons, lipids, etc (column 9-10).

It would have been obvious to one of ordinary skill in the art at the time of the invention to dissolve xenon in a fluid such as perfluorocarbon prior to hyperpolarizing the xenon in the methods of Ardenkjaer-Larson. One would have been motivated to do so because Pines teaches that it can be advantageous to dissolve a noble gas in a liquid prior to hyperpolarizing the noble gas (column 9). One would have had a reasonable expectation of success in doing so because Ardenkjaer-Larson teaches that hyperpolarization could be done in either liquid or solid form, the radical could be added in pure form or bound to a matrix (column 20).

#### Conclusion

No claims are allowed at this time.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leah Schlientz whose telephone number is (571)272-9928. The examiner can normally be reached on Monday-Tuesday and Thursday-Friday 9 AM-5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/532,563 Page 5

Art Unit: 1618

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/ Supervisory Patent Examiner, Art Unit 1618

LHS